Clinical trial
A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites
NCT02596321 is registered in ClinicalTrials.gov with Abbott as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites
- Lead sponsor
- Abbott
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2015
- Completion date
- June 30, 2016
- Enrollment
- 112 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.